---
title: "China TCM Wins Shareholder Approval for 2026–2028 Financial, Purchase and Supply Frameworks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274505643.md"
description: "China Traditional Chinese Medicine Holdings Co. Limited has received shareholder approval for its 2026–2028 Financial Services Framework Agreement and new Master Purchase and Supply Agreements during an extraordinary general meeting on February 2, 2026. Despite major shareholder CNPGC abstaining from voting, the resolutions were passed with around 99% approval, ensuring operational continuity and compliance with Hong Kong listing requirements. The current analyst rating for the stock (HK:0570) is a Hold with a price target of HK$2.00, and the company has a market cap of HK$10.37B."
datetime: "2026-02-02T11:08:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274505643.md)
  - [en](https://longbridge.com/en/news/274505643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274505643.md)
---

# China TCM Wins Shareholder Approval for 2026–2028 Financial, Purchase and Supply Frameworks

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

China Traditional Chinese Medicine Holdings Co ( (HK:0570) ) has shared an update.

China Traditional Chinese Medicine Holdings Co. Limited announced that all resolutions put to shareholders at its extraordinary general meeting on 2 February 2026 were duly passed by poll. Shareholders approved, confirmed and ratified the company’s 2026–2028 Financial Services Framework Agreement, as well as new Master Purchase and Master Supply Agreements and their respective annual caps for the three financial years ending 31 December 2028, despite major shareholder CNPGC and its associates abstaining from voting on the relevant resolutions. The strong support for the purchase and supply arrangements, with approval rates around 99%, provides the group with formally sanctioned frameworks for intra-group financial services and trading activities over the next three years, underpinning operational continuity and related-party transactions in line with Hong Kong listing requirements.

The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.

**More about China Traditional Chinese Medicine Holdings Co**

China Traditional Chinese Medicine Holdings Co. Limited is a Hong Kong-incorporated company listed on the Hong Kong Stock Exchange, operating in the traditional Chinese medicine sector. It is involved in the manufacturing, supply and distribution of traditional Chinese medicine products and related services, serving healthcare and consumer markets in China and potentially other regions through its listed platform.

**YTD Price Performance:** -1.44%

**Average Trading Volume:** 13,339,631

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$10.37B

Learn more about 0570 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [00570.HK](https://longbridge.com/en/quote/00570.HK.md)

## Related News & Research

- [China Traditional Chinese Medicine Holdings Co. Limited Held Extraordinary General Meeting](https://longbridge.com/en/news/274502178.md)
- [Xspray Pharma convenes 2026 AGM, sets voting rules and agenda](https://longbridge.com/en/news/282149317.md)
- [Medivir Calls 2026 AGM, Details Shareholder Voting Procedures and Capital Structure](https://longbridge.com/en/news/281995277.md)
- [NOTICE OF CONVENING OF THE REMOTE MEETING OF BONDHOLDERS OF UAB "KVARTALAS" (ISIN CODE LT0000411167) ON 6 MAY 2026](https://longbridge.com/en/news/282563733.md)
- [Flare (FLR) - FIP.16 Vote - 17 April 2026](https://longbridge.com/en/news/282392802.md)